Business
SCYNEXIS to Present Positive Interim Data from the Phase 3 FURI Study of Oral Ibrexafungerp at IDWeek 2022
JERSEY CITY, N.J., Oct. 11, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and
About this update from Scynexis, Inc.
[{"type":"text","content":"JERSEY CITY, N.J., Oct. 11, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that interim data from the Phase 3 FURI study of oral ibrexafungerp for the treatment of patients intolerant of, or with fungal disease refractory to, standard antifungal therapy will be presented during IDWeek 2022 being held in Washington, D.C October 19-23, 2022. Title: All-Cause Mortality in Patients with Invasive Candidiasis or Candidemia from an Interim Analysis of a Phase 3 Open-label Study (FURI)Format: Poster Presenter: Jurgen Prattes, MD, University of GrazSession: Medical MycologyDate/Time: Thursday October 20, 2022, 12:15 PM - 1:30 PM EDTLocation: Walter E. Washington Convention Center in Exhibit Hall BC Title: Oral Ibrexafungerp Outcomes by Fungal Disease in Patients from an Interim Analysis of a Phase 3 Open-label Study (FURI) Format: Oral PresentationPresenter: George Thompson, MD, University of California, DavisSession: Antifungal Clinical Trials & PK/PD StudiesDate/Time: Friday October 21, 2022, 10:30 AM – 11:45 AM EDTLocation: Walter E. Washington Convention Center in 147 AB Title: Ibrexafungerp Update Format: Oral PresentationPresenter: Nkechi Azie, MD, MBA, FDISA, SCYNEXISSession: New Antimicrobials and ID Diagnostics in the Pipeline – FungalDate/Time: Saturday October 22, 2022, 8:00 AM – 8:10 AM EDTLocation: Walter E. Washington Convention Center in 145 AB For more information, see the IDWeek 2022 website here. About Ibrexafungerp Ibrexafungerp is an antifungal agent and the first representative of a novel class of structurally-distinct glucan synthase inhibitors, triterpenoids. This agent combines the well-established activity of glucan synthase inhibitors with the potential flexibility of having oral and intravenous (IV) formulations. Ibrexafungerp is in late-stage development for multiple indications, including life-threatening fungal infections caused primarily by Candida (including C. auris) and Aspergillus species in hospitalized patients. It has demonstrated broad-spectrum antifungal activity, in vitro and in vivo, against multidrug-resistant pathogens, including azole- and echinocandin-resistant strains. The FDA granted Qualified Infectious Disease Product (QIDP) and Fast Tr...